Trial Condition(s):

Venous thrombosis, Pulmonary Embolism, Atrial Fibrillation, Acute Coronary Syndrome

Study of Rivaroxaban use and potential adverse outcomes in routine clinical practice (Germany)

Bayer Identifier:

16159

ClinicalTrials.gov Identifier:

NCT01947959

EudraCT Number:

Not Available

Study Completed

Trial Purpose

This prospective cohort study will provide information
about: characteristics of Rivaroxaban use in patients
who are prescribed Rivaroxaban for the first time
compared to patients who are prescribed
Phenprocoumon for the first time, the occurrence of
intracranial haemorrhage, gastrointestinal and urogenital
bleeding, and the occurrence of non-infective liver
disease.

Inclusion Criteria
-  All male and female patients who have been prescribed for the first time either Rivaroxaban or standard of care from the date of market authorization of rivaroxaban to Dec 31, 2017
Exclusion Criteria
-  Patients who have any record of being dispensed their index drug in the year before index date (i.e. cohort entry), or who qualify for both cohorts on the same day

Trial Summary

Enrollment Goal
665533
Trial Dates
black-arrow
Phase
4
Could I receive a placebo?
No
Products
Xarelto (Rivaroxaban, BAY59-7939)
Accepts Healthy Volunteers
No

Where to Participate

Loading...
Locations
Status
LocationsStatus
Locations

Investigative Site

Many Locations, Germany

Status
Completed
 

Trial Design